Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

AA-5-HTN-arachidonoylserotonin

FAAH inhibitor (IC50 5.6 µM) and TRPV1 antagonist (IC50 37 to 40 nM).

Level of detail

C₃₀H₄₂N₂O₂

CAS 187947-37-1

Family
ECS pharmacological toolEnzyme inhibitor
Molar mass
462.70 g/mol

Updated on

In plain terms

N-arachidonoyl serotonin is a molecule that acts in two ways at once: it slows the enzyme that destroys anandamide, the cannabinoid made by the body, and it blocks a channel activated by capsaicin. Described in 1998 as a laboratory molecule, it was later detected in small amounts in the gut of pigs and mice. In rats and mice it showed analgesic activity in pain models; no study in humans was found.

Receptors and activity

Target network

FAAHInhibitorIC50 = 5.6 µM · ratFAAH from RBL-2H3 cells (rat basophilic leukaemia), [14C]anandamide; 12.0 µM on FAAH from mouse N18TG2 neuroblastoma cells (the most active of the series, lower bound of the 12.0-26 µM range in the abstract); mixed-type, tight-binding, non-covalent inhibitor
  • Blocks or inhibits

The lower the cited value, the closer the target sits to AA-5-HT: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of AA-5-HT.

Brain, side view
Body, front view
Blood

FAAHFAAH found in 7 regions of the body

  1. CortexpresentCortical pyramidal neurons1
  2. Basal gangliapresentStriatal neurons1
  3. HypothalamuspresentPresent in hypothalamic nuclei1
  4. CerebellumpresentPurkinje cells and cerebellar layers1
  5. BrainstempresentInferior olivary nuclei1
  6. Adipose tissuepresentExpressed in mature adipocytes2
  7. BonepresentPresent on osteoclasts3

Cited values

  1. FAAHInhibitorIC50 = 5.6 µM · rat21 out of 100

    Bisogno et al., Biochem Biophys Res Commun 1998 (new tab) · FAAH from RBL-2H3 cells (rat basophilic leukaemia), [14C]anandamide; 12.0 µM on FAAH from mouse N18TG2 neuroblastoma cells (the most active of the series, lower bound of the 12.0-26 µM range in the abstract); mixed-type, tight-binding, non-covalent inhibitor

  2. TRPV1AntagonistIC50 = 40 nM · rat and human57 out of 100

    Maione et al., Br J Pharmacol 2007 (new tab) · recombinant TRPV1 in HEK-293 cells, against 100 nM capsaicin; 37 to 40 nM depending on species (the abstract does not attribute them); upper value retained

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Measured effects

Not characterised. No placebo-controlled human trial has measured the effects of AA-5-HT, so no level is shown.

Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method

Pharmacology

N-arachidonoyl serotonin (AA-5-HT) inhibits FAAH and antagonises the TRPV1 channel. Bisogno and colleagues described it in 1998 among five artificially functionalised polyunsaturated fatty acids: it was the most active of the four new FAAH inhibitors reported (IC50 12.0 µM on FAAH from N18TG2 cells, 5.6 µM on that from RBL-2H3 cells). Resistant to hydrolysis by FAAH, it behaved as a tight-binding, non-covalent mixed inhibitor, with no effect on cytosolic phospholipase A2 or on anandamide uptake, and it did not activate CB1. In 2007, Maione and colleagues showed that it antagonises recombinant rat and human TRPV1 in HEK-293 cells (IC50 37 to 40 nM against 100 nM capsaicin) and that it had analgesic activity in the pain models used in rats and mice (formalin test, chronic constriction of the sciatic nerve in rats). This activity was partly linked to FAAH inhibition, elevated tissue anandamide and indirect CB1 activation (reversed by AM251), and also appeared to involve TRPV1 activation followed by desensitisation or direct antagonism of the channel (effects reversed by capsazepine and 5'-iodo-resiniferatoxin, or mimicked by them alone). These are preclinical results in rodents; no study in humans was found. An endogenous presence of AA-5-HT, with other N-acyl serotonins, has been reported in the jejunum and ileum of pigs and mice (Verhoeckx et al. 2011).

History

Source
Described first as a synthetic compound: in 1998 it was one of five artificially functionalised polyunsaturated fatty acids (Bisogno et al. 1998). It was later detected as an endogenous compound, with other N-acyl serotonins, in the jejunum and ileum of pigs and mice (Verhoeckx et al. 2011). No authorised human use or circulation as a consumer product was found.

Origin

Research tool

No plant pathway. In pigs and mice, N-acyl serotonins including AA-5-HT form in intestinal tissue incubations, and this formation increases when serotonin is added; in mice, the pattern formed depends on the fatty acids of the diet (Verhoeckx et al. 2011). The abstract of that study does not name the responsible enzyme. Structurally it is an N-acyl serotonin: the amide of arachidonic acid and serotonin.

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Enzyme inhibitor

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

Arachidonoyl serotonin (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

Common name
N-arachidonoylserotonin
Other names
AA-5-HT · N-arachidonoyl serotonin · AA-5HT

Identifiers

Formula
C₃₀H₄₂N₂O₂
CAS
187947-37-1
InChIKey
QJDNHGXNNRLIGA-DOFZRALJSA-N
SMILES
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCCC1=CNC2=C1C=C(C=C2)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.